OTC · Biotechnology

HAVN Life Sciences Inc. (HAVLF) Stock

$0.00 OTC: HAVLF Healthcare

HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms.

Valuation

MetricValue
Price$0.00
Market Cap$2565
P/E Ratio-0.01
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-0.44
52-Week High$0.01
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-234.52%
ROA-30.27%
ROCE-284.27%
Gross Margin35.54%
Operating Margin5362.73%
Net Margin0.00%
Debt/Equity0.03
Current Ratio2.68

Annual Financials (USD)

Metric202020212022
Revenue$0$0$0
Operating Profit$0$-30.0M$-10.0M
Net Profit$0$-30.0M$-22.0M
EPS$-0.02$-8.47$-5.25
Op Margin——-3548.4%

Balance Sheet (USD)

Metric202020212022
Total Assets$2.0M$14.0M$4.0M
Total Liabilities$0$1.0M$1.0M
Cash$2.0M$9.0M$1.0M
Borrowings$0$0$0

Cash Flow (USD)

Metric202020212022
Operating Cash Flow$0$-10.0M$-8.0M
Investing Cash Flow$0$0$-2.0M
Financing Cash Flow$0$5.0M$0
Net Cash Flow$2.0M$8.0M$-8.0M
Free Cash Flow$0$-10.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.02
FCF Yield-691.30%
Quick Ratio2.62
Interest Coverage-152.94
Return 1Y-95.00%
Return 3Y-99.30%
Return 5Y—

Ownership

Insiders Held3.51%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
AdvisorShares Trust-AdvisorShares Psychedelics ETF3,3332022-08-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADXSAyala Pharmaceuticals, Inc. $0.60 +0.00% -0.08 $25.71M 0.00%
ARUXFAcrux Limited $0.02 +0.00% -1.90 $6.78M 0.00%
AXIMAXIM Biotechnologies, Inc. $0.00 — -2.00 $1.02M 0.00%
NRPRResilient Healthcare Corp $0.02 +0.00% — $2.11M 0.00%
PKTXProtoKinetix, Incorporated $0.00 — -1.00 $156632 0.00%

About HAVN Life Sciences Inc.

HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-controlled methodologies for extracting these psychoactive molecules, with a specific focus on Psilocybe mushroom species and their key constituents such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health products utilizing unregulated ingredients. Founded in 2020, HAVN Life Sciences' operations are headquartered in Richmond, Canada.

HAVN Life Sciences Inc. (HAVLF) stock trades at $0.00 with a market capitalization of $2565. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.01, reflecting a net loss over the last twelve months, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, HAVN Life Sciences Inc. generates a return on equity (ROE) of -234.52% (negative, reflecting a net loss), return on capital employed of -284.27%, an operating margin of 5362.73%.

Official website: www.havnlife.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.